27.11
-0.61(-2.20%)
Currency In USD
| Previous Close | 27.72 |
| Open | 27.72 |
| Day High | 28 |
| Day Low | 26.71 |
| 52-Week High | 28 |
| 52-Week Low | 8.75 |
| Volume | 2.24M |
| Average Volume | 2.82M |
| Market Cap | 2.33B |
| PE | -14.9 |
| EPS | -1.82 |
| Moving Average 50 Days | 16.7 |
| Moving Average 200 Days | 14.41 |
| Change | -0.61 |
If you invested $1000 in Liquidia Corporation (LQDA) since IPO date, it would be worth $2,442.34 as of August 19, 2025 at a share price of $27.11. Whereas If you bought $1000 worth of Liquidia Corporation (LQDA) shares 5 years ago, it would be worth $4,832.44 as of August 19, 2025 at a share price of $27.11.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025
GlobeNewswire Inc.
Aug 05, 2025 12:30 PM GMT
MORRISVILLE, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its second qua
Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™
GlobeNewswire Inc.
Jun 23, 2025 8:34 PM GMT
MORRISVILLE, N.C., June 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, today announced the receipt of an additional $50.0
Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD
GlobeNewswire Inc.
Jun 02, 2025 10:30 AM GMT
YUTREPIA now available to be prescribed to patients via specialty pharmaciesFDA approved YUTREPIA on May 23, 2025Court denies United Therapeutics’ request for preliminary injunction and a temporary restraining order, clearing the path for full commer